All In Biotech

Drug Trial Radar · NCT06972264

Safety and Efficacy of VDPHL01 in Males With AGA

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia

Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Mar 11, 2025

Primary completion

Dec 2026

Study completion Jul 2027

Sponsor

Lead sponsor
Veradermics, Inc.Industry
Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).

Conditions

  • Androgenetic Alopecia
  • AGA
  • Male Pattern Baldness

Interventions

  • VDPHL01Drug

    VDPHL01 Extended Release (ER) Tablet

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in non-vellus Target Area Hair Counts (TAHC)Time frame: Month 6
  2. Subjects Evaluation of Treatment BenefitTime frame: Month 6

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Site 73

    Birmingham, Alabama

  • Site 89

    Birmingham, Alabama

  • Site 77

    Phoenix, Arizona

  • Site 69

    Encino, California

  • Site 64

    Manhattan Beach, California

  • Site 93

    Northridge, California

  • Site 66

    Santa Monica, California

  • Site 94

    Thousand Oaks, California

  • Site 71

    Boca Raton, Florida

  • Site 86

    Coral Gables, Florida

  • Site 62

    Coral Gables, Florida

  • Site 99

    Miami, Florida

  • Site 54

    Ocala, Florida

  • Site 96

    Tamarac, Florida

  • Site 90

    Sandy Springs, Georgia

  • Site 61

    Chicago, Illinois

  • Site 53

    Clarksville, Indiana

  • Site 55

    Plainfield, Indiana

  • Site 79

    Leawood, Kansas

  • Site 52

    Louisville, Kentucky

  • Site 75

    New Orleans, Louisiana

  • Site 84

    Glenn Dale, Maryland

  • Site 87

    Rockville, Maryland

  • Site 80

    Chestnut Hill, Massachusetts

  • Site 59

    Quincy, Massachusetts

  • Site 68

    Clinton Township, Michigan

  • Site 83

    Troy, Michigan

  • Site 82

    Hickory, North Carolina

  • Site 92

    Huntersville, North Carolina

  • Site 72

    Cincinnati, Ohio

  • Site 57

    Portland, Oregon

  • Site 81

    East Greenwich, Rhode Island

  • Site 60

    Anderson, South Carolina

  • Site 95

    Hermitage, Tennessee

  • Site 76

    Austin, Texas

  • Site 51

    Austin, Texas

  • Site 74

    College Station, Texas

  • Site 67

    Dallas, Texas

  • Site 78

    Plano, Texas

  • Site 88

    San Antonio, Texas

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.